Genentech, Tercica win damages in patent suit

Insmed Inc. infringed three patents covering a treatment for abnormally short children, a jury said in a lawsuit brought by Genentech Inc. and Tercica Inc.

The jury in federal court in Oakland awarded San Francisco-based Genentech and Brisbane, Calif.-based Tercica $7.5 million in damages and a percentage of future sales of the treatment.

Richmond, Va.-based Insmed’s Iplex and Tercica’s product, called Increlex, are growth drugs used to treat about 6,000 short children.